Close Menu

KRAS Biomarkers

News and reporting on KRAS biomarkers.

The company, whose technology enables the selective amplification of mutant DNA, will use the financing to ramp up its commercialization work and build its product portfolio.

A new study of colorectal cancer tissue samples and plasma shows peptide-nucleic-acid-PCR is more sensitive.

EntroGen this week announced the availability of expanded colorectal cancer screening products.

The Multiple Myeloma Research Foundation is hoping that an open-access research portal containing detailed longitudinal clinical and genomic data from multiple myeloma patients will spur collaborative research that advances much needed molecularly-targeted treatments.

Trovagene is using RainDance Technologies' RainDrop Digital PCR system to develop and eventually run a cell-free transrenal BRAF mutation assay out of Trovagene's CLIA lab, the companies said this week.

Transgenomic announced this week that it has signed an agreement with Amgen to develop an IVD test to identify NRAS and KRAS mutated patients with advanced colorectal cancer using its RAScan kits.

In the first quarter of this year, pharmacogenetically targeted cancer drugs Xalkori and Zelboraf had marked increases in revenues from the previous year's quarter.

UK-based clinical diagnostics developer Lab21 said last week that it has inked an agreement with IntegraGen to develop a microRNA assay for colorectal cancer designed to improve patient outcomes.

Qiagen said this week that GE Healthcare subsidiary Clarient will offer Qiagen's Therascreen KRAS RGQ PCR kit as a companion diagnostic to guide the use of Erbitux (cetuximab) as a treatment in patients with metastatic colorectal cancer.

Pages

The Washington Post reports that the CDC's SARS-CoV-2 test issues reflect earlier ones it had with Zika virus testing.

NPR writes that even with thousands of new COVID-19 papers, each should be evaluated based on its own quality.

Researchers traced a gene cluster linked to COVID-19 severity to Neanderthals, the New York Times reports.

In PNAS this week: soil bacteria-derived small molecules affect centrosomal protein, microfluidics approach for capturing circulating tumor cells, and more.